Celsion Initiates Phase III Liver Cancer Study
Posted on: Thursday, 13 March 2008, 06:00 CDT
Celsion has reported that two clinical sites are currently screening patients after receiving IRB approval for the Phase III study of ThermoDox in the treatment of non-resectable hepatocellular carcinoma.
The trial is a randomized, double-blinded, dummy-controlled study designed to evaluate the efficacy and safety of ThermoDox in combination with radiofrequency ablation (RFA) compared to RFA-alone. This 40 center, 600-patient study is projected to enroll patients over approximately an 18 month period, and will conclude by fourth quarter of 2009.
In addition, the submission of Celsion's clinical trial authorization application for the Phase III protocol has been accepted by China SFDA, with authorization to enroll patients expected in August 2008.
Source: Datamonitor
Related Articles
- Study: Patients don't discuss hospice care
- Study: Patient Harm More Common with Patient-Controlled Pain Medication
- Derma Sciences Enrolls First Patient in DSC127 Phase II Study
- Y's Therapeutics Completes Study Patient Enrollment
- Study: Patients Shouldn't Give Up on Banishing Depression
- Sudafed Beats Singulair in Merck-Funded Allergy Study ; Patients Felt Better Using Pfizer Drug
- Cyberonics Announces Closure of Investigational Device Exemption (IDE) for Treatment-Resistant Depression (TRD), Lifetime Reimbursement Guarantee for All TRD IDE Study Patients and $15 Million TRD Indigent Care Program
- Many Discharged Patients Do Not Know Diagnoses, Medications, Side Effects
- The Asthma and Allergy Foundation of America (AAFA) Available to Comment on Asthma Study in the New England Journal of Medicine (NEJM)
- Endpoints Met in First Stage of ADVENTRX CoFactor Phase II Metastatic Colorectal Cancer Study; Patient Enrollment Completed in Phase II Study
 |
 |
User Comments (0)
RSS Feeds